Ocular oncology involves the study and treatment of tumors that occur in or around the eye. These tumors can range from harmless to potentially life-threatening, and may cause vision loss or loss of the eye itself.

Due to the complex nature of ocular oncology, our faculty includes experts in cornea, ophthalmic plastic surgery, pathology, and retina. Mass. Eye and Ear researchers and clinician scientists have experience with a range of conditions, including ocular surface tumors, uveal melanoma, orbital tumors and inflammation, and retinoblastoma.

Researchers at Mass. Eye and Ear have made several groundbreaking advances in the field of ocular oncology, including the identification and isolation of the retinoblastoma (Rb) gene—the first known tumor-suppressor gene, which formed an important cornerstone in the molecular basis of cancer.  Below are highlights of our accomplishments of the past 2o years:

• Conducted the first adjuvant trial investigating the role of interferon for reducing the risk of metastasis from uveal melanoma
• Contributed to the characterization of BAP1 tumor predisposition syndrome and defined the prevalence of germline BAP1 mutations in patients with uveal melanoma
• Evaluated the role of antivascular endothelial growth factor therapy in preventing vision loss due to radiation retinopathy in patients with choroidal melanoma
• Performed first in-human study of a novel targeted therapy for uveal melanoma
• Investigated inhibitory effect of verteporfin on various tumor cell lines

Tumors of the eye may be diverse and varied in their clinical presentation. Equally diverse are the diagnostic modalities and treatment options for them. In the 1980s and early 1990s, all that was available for retinoblastoma was radiation and radical surgery like enucleation. From those days, treatment has evolved today to become not only more effective but also have minimal collateral damage and systemic side-effects. Treatment of retinoblastoma has progressed with the aim of treatment no longer being “life salvage.” Today, the aim is “globe salvage” or even “vision salvage” in retinoblastomas; more of which Kaliki et al. have discussed in detail this issue. Selective intra-arterial chemotherapy, intravitreal chemotherapy, neo-adjuvant chemotherapy, and plaque brachytherapy are some of the newer advances in the field of ocular oncology.

The journal invites different types of articles including original research article, review articles, short note communications, case reports, Editorials, letters to the Editors and expert opinions & commentaries from different regions for publication. A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing.

Manuscripts can be uploaded directly through mail id: ophthalmologist@eclinicalsci.com 

Online Submission: https://www.pulsus.com/submissions/ophthalmologist-clinical therapeutic-journal.html

Media Contact
Sarah Rose
Journal Manager
The Ophthalmologist: Clinical and Therapeutic Journal
Email: ophthalmologist@eclinicalsci.com